Platinum-containing compounds, and related compositions and uses thereof

Abstract

Platinum-containing compounds are generally described. For example, compounds of Formula (II) are generally described. Inventive compositions and uses thereof are also described. For example, methods of treating cancer in a subject comprising administering to the subject a therapeutically effective amount of a compound of Formula (II) are generally described.

What is claimed is: 
     
       1. A compound of Formula (II): 
       
         
           
           
               
               
           
         
       
       or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof;
 wherein R 1 , R 2 , R 3 , R 4 , R 6 , and R 7  are each independently selected from the group consisting of hydrogen, alkyl, aryl, halogen, oxygen, hydroxy, alkoxy, aryloxy, siloxy, amino, alkylamino, arylamino, dialkylamino, diarylamino, imine, alkylimine, arylimine, and —OM; 
 wherein M is a cation; 
 wherein R 5  and R 8  are each independently selected from the group consisting of hydrogen, alkyl, aryl, halogen, oxygen, hydroxy, alkoxy, aryloxy, siloxy, amino, alkylamino, arylamino, dialkylamino, diarylamino, imine, alkylimine, arylimine, and —OM; 
 wherein R 9  and R 12  are each independently selected from the group consisting of —CR(R′)—, carbonyl, imine, alkylimine, and arylimine; 
 wherein R and R′ are independently selected from the group consisting of hydrogen, alkyl, aryl, halogen, hydroxy, alkoxy, aryloxy, siloxy, amino, alkylamino, arylamino, dialkylamino, and diarylamino; 
 wherein R 10  and R 11  are each independently selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, aryloxy, siloxy, amino, alkylamino, arylamino, dialkylamino, diarylamino, —(C═O)—(CH 2 ) k R 15 , —(CHOR 16 )—(CH 2 ) k R 15 , —(C═NR 16 )—(CH 2 ) k R 15 , —(CHNHR 16 )—(CH 2 ) k R 15 , and —(CHNR 16   2 )—(CH 2 ) k R 15 ; 
 wherein R 15  is selected from the group consisting of hydrogen, halogen, hydroxy, alkoxy, aryloxy, and siloxy; 
 wherein R 16  is selected from the group consisting of hydrogen, alkyl, aryl, and silyl; 
 wherein k is 0, 1, 2, or 3; 
 wherein R 13  and R 14  are each independently selected from the group consisting of hydrogen, halogen, alkyl, and aryl; 
 wherein A 1  and A 2  are each independently selected from the group consisting of oxygen, sulfur, and —NR 17 —; 
 wherein R 17  is selected from the group consisting of hydrogen, alkyl, and aryl; 
 wherein X 1  and X 2  are each independently selected from the group consisting of amino, alkylamino, arylamino, dialkylamino, diarylamino, oxygen, hydroxy, alkoxy, aryloxy, siloxy, sulfur, thiol, alkyl sulfide, aryl sulfide, alkyl sulfoxide, aryl sulfoxide, sulfinate, selenium, selenol, alkyl selenide, aryl selenide, alkyl selenoxide, aryl selenoxide, and seleninate; 
 wherein X 3  and X 4  are each independently selected from the group consisting of amino, alkylamino, arylamino, dialkylamino, diarylamino, heteroarylene, water, halide, carboxylate, hydroxide, alkoxide, aryloxide, siloxide, dialkyl sulfide, diaryl sulfide, alkyl aryl sulfide, dialkyl sulfoxide, diaryl sulfoxide, alkyl aryl sulfoxide, alkyl sulfinate, aryl sulfinate, alkyl sulfonate, aryl sulfonate, sulfite, sulfate, thiosulfate, dialkyl selenide, diaryl selenide, alkyl aryl selenide, dialkyl selenoxide, diaryl selenoxide, alkyl aryl selenoxide, selenite, and seleninate; 
 wherein Y and Z are each independently selected from the group consisting of hydroxide, alkoxide, aryloxide, siloxide, and halide; 
 wherein n is 0 or 1; 
 wherein m is 0 or 1; and 
 wherein M, Y, Z, A 1 , A 2 , X 1 , X 2 , X 3 , X 4 , R, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 , and/or R 17  are each independently optionally substituted. 
 
     
     
       2. The compound of  claim 1 , wherein X 1  and/or X 2  is amino. 
     
     
       3. The compound of  claim 1 , wherein R 2 , R 3 , R 4 , and/or R 13  are hydrogen. 
     
     
       4. The compound of  claim 1 , wherein R 6 , R 7 , and/or R 10  are hydroxy, and R 9  and/or R 12  are methylene. 
     
     
       5. The compound of  claim 1 , wherein A 1 , A 2 , R 5  and/or R 8  are oxygen, and R 1  is alkoxy. 
     
     
       6. The compound of  claim 1 , wherein R 11  is —(C═O)—(CH 2 ) k R 15 , R 15  is hydroxyl, and k is 1. 
     
     
       7. The compound of  claim 1 , wherein n and m are both 0. 
     
     
       8. A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the compound of  claim 1 , or a pharmaceutically acceptable salt, solvate, hydrate, polymorph, co-crystal, tautomer, stereoisomer, isotopically labeled derivative, or prodrug thereof. 
     
     
       9. The method of  claim 8 , wherein the cancer is selected from the group consisting of ovarian cancer, colorectal cancer, breast cancer, lung cancer, prostate cancer, osteosarcoma, and/or leukemia. 
     
     
       10. The method of  claim 8 , wherein the subject is a human.